Mutual of America Capital Management LLC Sells 1,612 Shares of Haemonetics Co. (NYSE:HAE)

Mutual of America Capital Management LLC lessened its holdings in Haemonetics Co. (NYSE:HAE) by 4.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,365 shares of the medical instruments supplier’s stock after selling 1,612 shares during the quarter. Mutual of America Capital Management LLC owned 0.06% of Haemonetics worth $2,682,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Haemonetics by 3.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,874 shares of the medical instruments supplier’s stock worth $1,956,000 after purchasing an additional 838 shares in the last quarter. ABLE Financial Group LLC lifted its position in shares of Haemonetics by 28.4% in the fourth quarter. ABLE Financial Group LLC now owns 7,251 shares of the medical instruments supplier’s stock worth $620,000 after purchasing an additional 1,606 shares in the last quarter. LVZ Inc. lifted its position in shares of Haemonetics by 9.4% in the fourth quarter. LVZ Inc. now owns 3,006 shares of the medical instruments supplier’s stock worth $257,000 after purchasing an additional 259 shares in the last quarter. Pacer Advisors Inc. increased its holdings in Haemonetics by 64.8% during the fourth quarter. Pacer Advisors Inc. now owns 9,098 shares of the medical instruments supplier’s stock worth $778,000 after buying an additional 3,579 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in Haemonetics during the fourth quarter worth $345,000. Institutional investors own 99.67% of the company’s stock.

Haemonetics Price Performance

NYSE:HAE opened at $83.50 on Friday. Haemonetics Co. has a one year low of $70.74 and a one year high of $95.26. The company has a market cap of $4.24 billion, a P/E ratio of 33.94, a P/E/G ratio of 1.99 and a beta of 0.36. The firm’s fifty day moving average price is $78.83 and its two-hundred day moving average price is $82.78. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.92 and a quick ratio of 1.76.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 EPS for the quarter, beating the consensus estimate of $0.94 by $0.10. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The firm had revenue of $336.20 million for the quarter, compared to the consensus estimate of $320.84 million. During the same period in the previous year, the company earned $0.85 earnings per share. The company’s quarterly revenue was up 10.1% on a year-over-year basis. Equities analysts expect that Haemonetics Co. will post 3.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HAE has been the topic of a number of recent analyst reports. Barrington Research restated an “outperform” rating and set a $105.00 target price on shares of Haemonetics in a report on Friday, April 12th. StockNews.com downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, TheStreet downgraded shares of Haemonetics from a “b-” rating to a “c+” rating in a report on Thursday, February 29th.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.